^
    Back
    Association details:
    Biomarker:CASP3 underexpression + BCL2 positive
    Cancer:Hodgkin Lymphoma
    Regimen: (bleomycin + dacarbazine + doxorubicin hydrochloride + vinblastine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    EHA 2018
    Title:

    ACTIVATED CASPASE-3 EXPRESSION BY HODGKIN AND REED-STERNBERG CELLS (HRS) IS A POWERFUL PROGNOSTIC FACTOR IN CLASSICAL HODGKIN LYMPHOMA (CHL) TREATED WITH ABVD OR EQUIVALENT REGIMENS

    Published date:
    05/17/2018
    Excerpt:
    Eligible patients had biopsy-proven cHL treated with ABVD or equivalent regimens….The 20-year FFP for patients whose tumors were aC3high/BCL2neg, either aC3low or BCL2pos, and aC3low/BCL2pos was 91% vs 84% vs 60% (p<0.0001)....The combination aC3low/BCL2pos defined a sizeable (~43% of patients) subgroup of advanced cHL with very poor outcome reflected by PFS<50%.